{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+care+with+blood+and+urine+sample+collection&page=2",
    "query": {
      "intervention": "Standard care with blood and urine sample collection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+care+with+blood+and+urine+sample+collection&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+care+with+blood+and+urine+sample+collection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T08:07:15.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03712605",
      "title": "Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2018-11-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 552,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712605"
    },
    {
      "nct_id": "NCT01380366",
      "title": "rHGH and Intestinal Permeability in Intestinal Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Short Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Somatropin",
          "type": "DRUG"
        },
        {
          "name": "Seven Day Food Diary",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Tests (standard of care)",
          "type": "PROCEDURE"
        },
        {
          "name": "Fasting",
          "type": "OTHER"
        },
        {
          "name": "Sugar Permeability Test",
          "type": "OTHER"
        },
        {
          "name": "Urine Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-10",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01380366"
    },
    {
      "nct_id": "NCT06330805",
      "title": "Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage IIB Prostate Cancer AJCC v8",
        "Stage IIC Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Contrast Agent",
          "type": "OTHER"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Physical Performance Testing",
          "type": "OTHER"
        },
        {
          "name": "Relugolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 70,
      "start_date": "2024-08-12",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06330805"
    },
    {
      "nct_id": "NCT04656873",
      "title": "Immuno-Oncology Database and Bioregistry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignancy",
        "Immune System Diseases",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires/Surveys",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2021-05-20",
      "completion_date": "2026-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04656873"
    },
    {
      "nct_id": "NCT04288427",
      "title": "5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia",
        "Prostate Hyperplasia",
        "Prostate Disease",
        "Prostate Hypertrophy",
        "Prostate Pain",
        "Lower Urinary Tract Symptoms",
        "Urinary Obstruction",
        "Urinary Tract Disease"
      ],
      "interventions": [
        {
          "name": "Finasteride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "50 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-09-25",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04288427"
    },
    {
      "nct_id": "NCT03569813",
      "title": "Pre-exposure Prophylaxis (PrEP) at Home",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "PrEP@Home System",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "MALE",
        "summary": "18 Years to 49 Years · Male only"
      },
      "enrollment_count": 318,
      "start_date": "2019-04-26",
      "completion_date": "2023-04-15",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Jackson, Mississippi + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03569813"
    },
    {
      "nct_id": "NCT02780128",
      "title": "Next Generation Personalized Neuroblastoma Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Next Generation Sequencing",
          "type": "GENETIC"
        },
        {
          "name": "Tumor Scans",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone marrow Tests",
          "type": "PROCEDURE"
        },
        {
          "name": "Physical Exam",
          "type": "OTHER"
        },
        {
          "name": "Eye Exam",
          "type": "OTHER"
        },
        {
          "name": "Labs",
          "type": "OTHER"
        },
        {
          "name": "Pregnancy Test",
          "type": "OTHER"
        },
        {
          "name": "Interviews",
          "type": "BEHAVIORAL"
        },
        {
          "name": "ECG",
          "type": "OTHER"
        },
        {
          "name": "Echocardiogram",
          "type": "OTHER"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "GENETIC",
        "OTHER",
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Yael P Mosse",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 66,
      "start_date": "2016-07",
      "completion_date": "2022-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780128"
    },
    {
      "nct_id": "NCT02970045",
      "title": "Norris ORIEN Total Cancer Care",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer Risk",
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Evaluation of Cancer Risk Factors",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2016-05-02",
      "completion_date": "2037-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02970045"
    },
    {
      "nct_id": "NCT07332351",
      "title": "Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Stage II Bladder Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Nadofaragene Firadenovec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Radical Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2026-12-01",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07332351"
    },
    {
      "nct_id": "NCT02055105",
      "title": "Modulation of Molecular Fingerprinting in Pediatric Sepsis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Inflammatory Response Syndrome"
      ],
      "interventions": [
        {
          "name": "miRNA in Sepsis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Phoenix Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-03",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-11T08:07:15.470Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02055105"
    }
  ]
}